Acadia Pharmaceuticals (ACAD) Stock Selloff Is Over Done Says UBS, 'the level of sell-off is surprising to us'
Tweet Send to a Friend
UBS analyst Ashwani Verma lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $33.00 (from $35.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
